stalled for 4 weeks at 2.5mg and I refuse to panic this time
stalled for 4 weeks at 2.5mg and I refuse to panic this time, which sounds obvious until you try to state the evidence for it.
Pulling the figures out of the title: 4 weeks and 2.5mg. All of it is written down as it happened rather than reconstructed.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
long-acting amylin is the whole point of the molecule
long-acting amylin is the whole point of the molecule
Adding the standing caveat — nothing here is approved standalone and research material is not for human use.
Independent result added to the log. Thank you for paying for it — there are very few on this compound.
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Dosing intuitions from the GLP-1 boards do not transfer.
Agreed, and the combination arms are where the interesting numbers actually live.
Dosing intuitions from the GLP-1 boards do not transfer.
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
Sent a vial to PeptideMeter because there was almost nothing on file for this compound. 98.7% against a claimed 98.0%, and I posted it because the log needs entries.